Stockreport

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Neumora Therapeutics, Inc.  (NMRA) 
PDF Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's [Read more]